Stock Analysis
Yantai Zhenghai Biotechnology Second Quarter 2024 Earnings: EPS: CN¥0.26 (vs CN¥0.31 in 2Q 2023)
Yantai Zhenghai Biotechnology (SZSE:300653) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥108.4m (down 6.1% from 2Q 2023).
- Net income: CN¥45.7m (down 19% from 2Q 2023).
- Profit margin: 42% (down from 49% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.
- EPS: CN¥0.26 (down from CN¥0.31 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Yantai Zhenghai Biotechnology Earnings Insights
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China.
Performance of the Chinese Biotechs industry.
The company's shares are up 3.0% from a week ago.
Risk Analysis
Be aware that Yantai Zhenghai Biotechnology is showing 1 warning sign in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:300653
Yantai Zhenghai Biotechnology
Engages in the research and development, production, and marketing of regenerative medical materials in China.